ChinaBio® Daily Update
Contents
Korea’s Green Cross to Build Cell Therapy Facility in China
Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.
Green Cross of South Korea will build a new cell therapy manufacturing facility in the Guian New Area of Guizhou province, located in China’s southwest corner. In South Korea, the company already produces cell therapy projects including T cell, NK cell, dendritic cell and stem cells. The new China facility will offer cellular therapeutic products for clinical studies and commercial supply, in response, the company says, to the increasing global interest in cellular therapeutic drugs as treatments for serious diseases. More details….
Stock Symbol: (KRX: 5280)
Share this with colleagues:
More Recent Articles
Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.
Scanadu Raises $35 Million from China Investors for Mobile Diagnostic DeviceShenzhen Hepalink Pharma Enters $441 Million Deal for Resverlogix CV DrugChina Cord Blood Receives $512 Million Take-Private OfferWeek in Review: Haohai Biological Schedules $305 Million Hong Kong IPOFor Big Pharma in China, Innovation is in the Eye of the Beholder
Partner Events
May 19-21, 2015
Hong Kong, China
Not a ChinaBio®Today Subscriber?
Website access to all current articles and commentaryFull access to over 2000 archived articles on the biotech industry
Greg B. Scott
Executive Editor
ChinaBio® Today
ChinaBio and ChinaBio Today are trademarks of ChinaBio LLC